East Norriton, PA, May 13, 2010 – Tengion, Inc. (Nasdaq: TNGN), a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced it will release its first quarter 2010 financial report before market open on Tuesday, May 18, 2010. Tengion will host a conference call at 9 am Eastern Time in conjunction with the release.
Conference Call Access:
Date: May 18, 2010
Time: 9:00 am Eastern Time
Domestic Dial-in: (888) 680-0869
International Dial-in: (617) 213-4854
Passcode: 45856973
This conference call will be webcast live and archived on Tengion's web site at http://www.tengion.com/ until June 1, 2010.
About Tengion
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables us to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Our product candidates eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in March 2010 for its lead product candidate, the Neo-Urinary Conduit, an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for its Neo-Bladder Augment for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.